Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

The objective of this Phase II study is to assess the potential of asciminib in managing CML-CP or CML-AP in patient carrying the T315I mutation. The presence of this mutation introduces treatment difficulties due to the limited available options. The study seeks to collect additional data on the effectiveness and safety of asciminib for these patients. By determining the drug's capacity to manage the disease and enhance patients outcomes, the study is designed to fill the unmet medical need and potentially offer a new therapeutic path for patients at a treatment deadlock.

Trial Details

NCT ID
NCT06514534
Phase
PHASE2
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • ABL001/Asciminib
Locations (sample)
  • Bordeaux, France|44.84124,-0.58046
  • Lille, France|50.63391,3.05512
  • Lyon, France|45.74906,4.84789
  • Nantes, France|47.21725,-1.55336
  • Paris, France|48.85341,2.3488

Key Eligibility Criteria

  • Signed informed consent must be obtained prior to participation in the study.
  • Male or female participants with a diagnosis of CML-CP or CML-AP ≥ 18 years of age.
  • Patients with CML-CP or CML-AP with history of documented T315I mutation after at least one TKI and are resistant, intolerant, or ineligible to pon…
  • Not already treated with asciminib or another any allosteric TKI

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →